NASDAQ:XLO Xilio Therapeutics Q2 2025 Earnings Report $0.74 -0.01 (-1.17%) Closing price 04:00 PM EasternExtended Trading$0.74 0.00 (-0.03%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Xilio Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.08Beat/MissMissed by -$0.08One Year Ago EPSN/AXilio Therapeutics Revenue ResultsActual Revenue$8.21 millionExpected Revenue$8.21 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AXilio Therapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time7:30AM ETUpcoming EarningsXilio Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xilio Therapeutics Earnings HeadlinesXilio Therapeutics sees cash runway into 1Q27September 9 at 11:39 AM | msn.comXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under ...September 9 at 11:39 AM | finance.yahoo.comTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that could thrive as the chaos unfolds after September 30.September 10 at 2:00 AM | Porter & Company (Ad)Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadSeptember 9 at 7:30 AM | globenewswire.comXilio Therapeutics (XLO) Has a New Rating from Leerink PartnersAugust 29, 2025 | theglobeandmail.comXilio Therapeutics Faces Nasdaq Equity Compliance ChallengeAugust 28, 2025 | tipranks.comSee More Xilio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email. Email Address About Xilio TherapeuticsXilio Therapeutics (NASDAQ:XLO) is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity. The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads. Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.View Xilio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Celsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? Upcoming Earnings Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
